Latest Stories
3 Reasons REVG is Risky and 1 Stock to Buy Instead
REV Group currently trades at $66.76 and has been a dream stock for shareholders. It’s returned 497% since January 2021, blowing past the S&P 500’s 79.5% gain. The company has also beaten the index over the past six months as its stock price is up 36.6% thanks to its solid quarterly results.
3 Reasons SXI is Risky and 1 Stock to Buy Instead
What a time it’s been for Standex. In the past six months alone, the company’s stock price has increased by a massive 46.4%, reaching $242.02 per share. This performance may have investors wondering how to approach the situation.
Philip Morris (PM): Buy, Sell, or Hold Post Q3 Earnings?
Philip Morris has followed the market’s trajectory closely, rising in tandem with the S&P 500 over the past six months. The stock has climbed by 9.2% to $172.32 per share while the index has gained 8.2%.
3 Reasons to Avoid MLM and 1 Stock to Buy Instead
Martin Marietta Materials trades at $618.09 per share and has stayed right on track with the overall market, gaining 7.3% over the last six months. At the same time, the S&P 500 has returned 8.2%.
3 Reasons to Sell LUCK and 1 Stock to Buy Instead
Over the past six months, Lucky Strike’s shares (currently trading at $8.92) have posted a disappointing 14.3% loss, well below the S&P 500’s 8.2% gain. This may have investors wondering how to approach the situation.
3 Reasons to Sell ARW and 1 Stock to Buy Instead
Over the past six months, Arrow Electronics’s stock price fell to $116.66. Shareholders have lost 9.4% of their capital, which is disappointing considering the S&P 500 has climbed by 8.2%. This was partly driven by its softer quarterly results and might have investors contemplating their next move.
3 Reasons ALL is Risky and 1 Stock to Buy Instead
Since July 2025, Allstate has been in a holding pattern, posting a small return of 0.9% while floating around $193.68. The stock also fell short of the S&P 500’s 8.2% gain during that period.
Clover Health (CLOV): Buy, Sell, or Hold Post Q3 Earnings?
Over the last six months, Clover Health’s shares have sunk to $2.60, producing a disappointing 13.5% loss - a stark contrast to the S&P 500’s 8.2% gain. This may have investors wondering how to approach the situation.
2 Reasons to Sell AMRX and 1 Stock to Buy Instead
Amneal has been on fire lately. In the past six months alone, the company’s stock price has rocketed 63.3%, reaching $13.34 per share. This was partly thanks to its solid quarterly results, and the performance may have investors wondering how to approach the situation.
Hayward (HAYW): Buy, Sell, or Hold Post Q3 Earnings?
Hayward trades at $16.50 per share and has stayed right on track with the overall market, gaining 10.2% over the last six months. At the same time, the S&P 500 has returned 8.2%.